Skip to main content
main-content

Respiratory

ERS Congress 2019

medwireNews attended the ERS International Congress 2019 in Madrid, Spain.
Watch our expert interviews on the major trials.

Expert interviews from ERS 2019

02-10-2019 | Asthma | Video

ERS 2019: Omalizumab has oral steroid-sparing, bronchial remodelling effects

Christian Domingo discusses data on omalizumab in oral corticosteroid-dependent allergic asthma; as well as reducing the steroid dose needed, supplementing with omalizumab was associated with improvements in symptoms and bronchial pathology and remodelling (6:13).

02-10-2019 | Respiratory | Video

ERS 2019: Cryobiopsy as good as surgical biopsy for ILD diagnosis

Lauren Troy summarises the results of the COLDICE study, also published in The Lancet, which showed transbronchial lung cryobiopsy has a high level of diagnostic accuracy compared with surgical lung biopsy for the diagnosis of interstitial lung disease (4:43).

02-10-2019 | Asthma | Video

ERS 2019: Three-in-one asthma inhaler efficacious

Christian Virchow discusses new data from the TRIMARAN and TRIGGER studies, also published in The Lancet, noting that even patients with severe airflow limitation gain benefit from the simplified treatment approach. (6:36).

01-10-2019 | Respiratory | Video

ERS 2019: Baseline eosinophils indicate long-term lung function

Ida Mogensen tells us how high blood eosinophil counts are related to increased declines in FEV1 and FVC over 20 years in a population-based cohort study (4:42).

01-10-2019 | Respiratory | Video

ERS 2019: uILD benefits from antifibrotic treatment

Toby Maher discusses the uILD phase 2 trial of pirfenidone in patients with progressive fibrosing unclassifiable interstitial lung disease, the results of which have been published in The Lancet (5:19).

30-09-2019 | Respiratory | Video

ERS 2019: Xenon and helium MRI detect sub-clinical cystic fibrosis lung abnormalities

Laurie Smith tells us the key findings of a study that looked at the relative sensitivities of xenon and helium MRI for the evaluation of sub-clinical lung disease in children and adults with cystic fibrosis (4:16).

29-09-2019 | Chronic obstructive pulmonary disease | Video

ERS 2019: Exacerbation history remains best predictor of COPD exacerbations

Peter Calverley talks us through a post hoc analysis of the DYNAGITO trial looking at whether baseline eosinophil counts could help predict moderate-to-severe exacerbations in patients treated with corticosteroids for chronic obstructive pulmonary disease (5:30).

29-09-2019 | Respiratory | Video

ERS 2019: Antifibrotic therapy improves long-term survival in IPF

Jürgen Behr discusses data from the INSIGHTS-IPF registry showing that, compared with patients who never received antifibrotic treatment for idiopathic pulmonary fibrosis, those who did experienced significantly better long-term survival (2:44).

20-11-2019 | Oncology | News | Article

More support for gefitinib–chemotherapy combination in EGFR-mutated NSCLC

Phase III study results suggest gefitinib in combination with chemotherapy improves outcomes versus gefitinib alone in patients with EGFR-mutated, advanced non-small-cell lung cancer.

12-11-2019 | Oncology | News | Article

Lung cancer undertreatment common in USA, regardless of clinical subtype

Between 2010 and 2014, more than a third of lung cancer patients in the USA received less intensive treatment than recommended, or indeed no treatment at all, shows an analysis of data from the US National Cancer Database.

08-11-2019 | Oncology | News | Article

Ensartinib could expand treatment options for ALK-positive NSCLC

At least half of patients with crizotinib-resistant ALK translocation-positive non-small-cell lung cancer respond to treatment with the new-generation ALK inhibitor ensartinib, including those with brain metastases, phase II study data show.

06-11-2019 | Respiratory | News | Article

Comorbidities play a large part in healthcare cost of severe asthma

Over half of the incremental healthcare costs associated with severe asthma relative to mild or no asthma can be attributed to comorbid conditions, indicate Canadian study findings.

Twitter Icon Follow medwireNews

Click here
Image Credits